Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) · National Institutes of Health
MEDIUM confidence
Researched 2026-07-22 22:42 · profile: researcher
Programme Thesis
This NIH R01 programme funds the development and validation of novel assay technologies and screening platforms to discover chemical probes, drugs, or immunomodulators for diseases with unmet medical need. It exists to bridge the gap between basic biological discovery and therapeutic development by supporting innovative, high-throughput, or high-content screening approaches that can identify lead compounds or tool molecules.
Selection Criteria
Significance (30%): Does the project address an important problem and advance the field? Innovation (25%): Are the assays, screening strategies, or technologies novel and potentially transformative? Approach (25%): Is the design, methodology, and data analysis plan rigorous and feasible? Investigator (15%): Does the PI have the expertise and track record to execute the work? Environment (5%): Are the resources and institutional support adequate? Additional criteria: Early-stage investigators receive special consideration; strong preliminary data expected; emphasis on reproducibility and statistical rigor.
Past Winners / Cohort Profiles
Typical awardees are established academic investigators (PhD or MD/PhD) at US universities or research institutes with extensive experience in assay development, high-throughput screening, medicinal chemistry, or pharmacology. Many have prior R01 funding, multiple publications in top journals, and collaborative teams including chemists and biologists. Named examples are not available on the page, but archetypes include a professor developing a phenotypic screen for neurodegenerative disease or a team creating a novel biosensor for kinase inhibitor discovery.
Ideal Candidate Fingerprint
The platonic ideal applicant is a mid-career or senior investigator at a US research institution with a strong publication record in assay development, a proven ability to manage large-scale screening projects, and access to core facilities (e.g., HTS, chemical libraries). They have preliminary data demonstrating assay feasibility, a clear translational hypothesis, and a multidisciplinary team including chemists and biologists. Early-stage investigators are eligible but must show exceptional promise and robust preliminary work.
Recommended Framing
Eniola Olutogun should frame their CCT model and IMPRINT platform as a novel, high-throughput computational assay for predicting addiction liability of compounds, directly addressing the programme's goal of discovering chemical probes or drugs. Emphasize the validated Bayesian/MCMC framework, the 85.8% reduction in encoding probability, and the potential to screen for safer analgesics or psychostimulants. Highlight the independent research track record, endorsements from leading neuroscientists (Berridge, Gershman), and the Africa/Nigeria angle as a unique perspective on global addiction burden, while acknowledging the need to partner with a US-based institution for R01 eligibility.
Watch Out
The R01 mechanism typically requires the applicant to be affiliated with a US institution (university, hospital, or research organization) as the prime applicant; Eniola is an independent researcher in Nigeria without a US institutional affiliation. This is a major eligibility concern. Additionally, the programme expects significant preliminary data from wet-lab assays, not solely computational models; Eniola's work is entirely in silico. The lack of a PhD or current graduate enrollment may also be a disadvantage against typical R01 investigators.